Aviir CEO Dr. Douglas Harrington To Present The Facts Concerning Heart Disease At The "Head to Toe" Women's Expo In Del Mar On November 10 Heart disease, the leading killer of women in the U.S., is also a major cause of disability and bankruptcy, according to Dr. Harrington
IRVINE, Calif., Nov. 9, 2012 /PRNewswire/ -- Dr. Douglas Harrington, CEO of Aviir Inc., leads an inspiring presentation at the Head to Toe Women's Expo on Saturday, November 10 at the Del Mar Fairgrounds to discuss America's leading threat to women: Heart Disease. Dr. Harrington's lecture "Everything You Ever Wanted to Know About Heart Disease But Were Afraid to Ask" provides a deeper insight into the disease and how women can empower themselves to improve their cardiovascular health. The presentation will began at 12 noon on the Style Stage.
As CEO of Aviir, Dr. Harrington brings more than 25 years of experience in the discovery and creation of unique laboratory tests to guide clinical decisions. Aviir is an Irvine-based biotechnology company, specializing in the development of innovative tests which are designed to give individuals personalized information to influence a preventative lifestyle. Dr. Harrington's mission is to use this information to encourage individuals to take responsibility for their own heart health.
GUARDaHEART Foundation will contract with Aviir to sponsor on-site heart risk assessments at the event. Since 1 out of every 3 individuals in the US has some form of heart disease, GUARDaHEART has launched the "Save The 1" movement. Designed to raise awareness for heart disease, this movement encourages individuals to consult their physician and learn more about their cardiac risk. With knowledge comes power to make critical lifestyle modifications that inspire life.
"Heart Disease remains the leading cause of death in the US, claiming almost 600,000 lives each year, yet many are unaware that 80% of heart disease is preventable through lifestyle modification," said Dr. Harrington. An innovative blood test will also be presented at the event, developed by Aviir through a Stanford University cardiology collaboration, which identifies an individuals' cardiac risk in a five-year timeframe. "This timeframe allows preventive measures to be implemented," continued Dr. Harrington. "Our mission is to improve healthcare and encourage timely preventive strategies by providing this unique medical information."
About Aviir, Inc.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.
ABOUT THE HEAD TO TOE WOMEN'S EXPO
The Women's Head to Toe Expo is an extraordinary event not to be missed. Show hours are Saturday, Nov. 10 from 10:00 a.m. to 5:00 p.m. and Sunday, Nov. 11 from 10 a.m. to 4 p.m. Tickets, available at the door, are $8.00 for adults, $7.00 for seniors, and children under 12 are free. Parking is $9.00 at the Del Mar Fairgrounds. For more information, visit www.headtotoewomensexpo.com or call (877) 491-0677.
For media inquiries, please contact:
Dina Scaglione (949) 398-6320
SOURCE Aviir, Inc.